• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Science & Research

  • Print
  • Share
  • E-mail

Good Clinical Practice Contacts

 

Office of Good Clinical Practice (OGCP)

Members of our staff:
  • Joanne Less, Ph.D., Director, Office of Good Clinical Practice
  • Janet Donnelly, CIP, RAC, Policy Analyst
  • Bridget Foltz, MS, MT(ASCP), Policy Analyst
  • Sara Goldkind, M.D., M.A., Senior Bioethicist
  • Doreen Kezer, M.S.N., Senior Health Policy Analyst
  • Patrick McNeilly, Ph.D., R.Ph., C.I.P., Senior Health Policy Analyst
  • Marsha Melvin, Policy Analyst
  • Kathleen (Swisher) Pfaender, R.N., J.D., Senior Health Policy Analyst
  • Jean Toth-Allen, Ph.D., Biophysicist
     
Contact the Office of Good Clinical Practice if you have:
  • general questions about FDA good clinical practice regulations and policy
  • general questions about the FDA clinical Bioresearch Monitoring Program, and specifically clinical investigator, Institutional Review Board (IRB), sponsor, monitor, and contract research organization programs
  • questions about or suggestions related to FDA's Information Sheets for IRB's and Clinical Investigators
  • questions about reports made pursuant to 21 CFR 56.108(b) and 56.113 involving an FDA-regulated product if you do not know which FDA Center has jurisdiction (e.g., drug, medical device, biological product), including:
    • unanticipated problems involving risks to subjects [21 CFR 56.108(b)(1)]
    • serious or continuing noncompliance by an investigator with FDA regulations or with the IRB's determinations [21 CFR 56.108(b)(2)]
    • suspension or termination of IRB approval of a protocol [21 CFR 56.108(b)(3)]
       
Questions about Good Clinical Practice

Submit questions via email, in writing, or direct them to our general telephone number. We try to respond to each question as soon as possible.

(Please note: FDA cannot comment about products that are in the review process. We cannot comment about clinical trials for specific products, diseases, or conditions. We cannot answer questions about when a new product subject to pre-market approval will be approved or not approved.)

E-mail:gcp.questions@fda.hhs.gov 
Telephone:301-796-8340
Facsimile:301-847-8640
Write:Food and Drug Administration
Office of Good Clinical Practice
Office of Special Medical Programs
10903 New Hampshire Ave., WO32-5103
Silver Spring, MD 20993

 

Biological Products

Bioresearch Monitoring Branch
Office of Compliance and Biologics Quality
Center for Biologics Evaluation and Research (CBER)
Telephone: 301-827-6221
Facsimile: 301-827-6748
 

Contact the Bioresearch Monitoring Branch for questions about:
  • The legal status of a test article
  • Human subject production regulations relating to biologics
  • CBER assigned IRB inspections
  • CBER assigned Clinical Investigator inspections
  • Reports made pursant to 21 CFR 56.108(b) and 56.113 involving a biologic product including:
    • unanticipated problems involving risks to subjects
    • serious or continuing noncompliance by an investigator with FDA regulations or with the IRB's determinations
    • suspension or termination of IRB approval of a protocol

 

Drug Products

Office of Scientific Investigations (OSI)
Office of Compliance
Center for Drug Evaluation and Research (CDER)
Telephone: 301-796-3150
Facsimile: 301-847-8748
Email:  CDER-OSI@fda.hhs.gov

Contact the Office of Scientific Investigations for questions about:
  • Human subject protection regulations pertaining to drugs (21 CFR Parts 50, 56, 312, 361)
  • CDER-assigned IRB inspections (e.g., FDA-483's)
  • Reports made pursuant to 21 CFR 56.108(b) and 56.113 involving a drug product including:
    • unanticipated problems involving risks to subjects [21 CFR 56.108(b)(1)]
    • serious or continuing noncompliance by an investigator with FDA regulations or with the IRB's determinations [21 CFR 56.108(b)(2)]
    • suspension or termination of IRB approval of a protocol [21 CFR 56.108(b)(3)]
  • reporting complaints related to human subject protection/Good Clinical Practice in FDA-regulated drug trials

 

Medical Devices

Division of Bioresearch Monitoring
Office of Compliance
Center for Device and Radiological Health (CDRH)
Phone: 301-796-5490
Fax: 301-847-8136
Web site: www.fda.gov/cdrh/comp/bimo.html
 

Contact the Division of Bioresearch Monitoring for questions about:
  • Human subject protection regulations pertaining to devices [21 CFR Parts 50, 56, and 812]
  • Informed consent, standard operating procedures, records and reports
  • Serious or continuing noncompliance by an investigator with FDA regulations or with the IRB's determinations involving a medical device [21 CFR 56.108(b)(2)]
  • Reporting complaints related to human subject protection/Good Clinical Practice in FDA-regulated medical device trial

 

CFSAN-regulated products

Bioresearch Monitoring Program
Office of Center Director
Center for Food Safety and Applied Nutrition (CFSAN)
Phone: 240-402-1757
Fax: 301-436-2668
 

Contact the Bioresearch Monitoring Program for questions about:
  • Human subject protection relating to CFSAN-regulated products. CFSAN-regulated products include:
    • food additives
    • color additives
    • infant formula
    • dietary supplements
  • Human subject protection relating to petitions for nutrient content claims and health claims
  • Reporting complaints related to the conduct of clinical trials of CFSAN-regulated products

 

New Animal Drugs

Premarket Compliance and Administrative Action Team
Center for Veterinary Medicine (CVM)
Phone: 240-276-9200
Fax: 240-276-9241
 

Contact the Premarket Compliance and Administrative Actions Team for questions about:
  • Good Clinical Practice regulations pertaining to new animal drugs for investigational use (21 CFR Part 511)
  • Reporting omplaints related to the conduct of studies with new animal drugs for investigational use

 

Enforcement Information

Division of Compliance Policy
Office of Enforcement
Office of Regulatory Affairs
Telephone: 240-632-6800
Fax: 240-632-6810
 

Contact the Division of Compliance Policy for questions about:
  • questions about the overall FDA Bioresearch Monitoring Program, and specifically the Good Laboratory Practice (GLP, nonclinical laboratories) Program
  • general Bioresearch Monitoring program enforcement issue